{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:46:46Z","timestamp":1784598406467,"version":"3.55.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Remimazolam is an intravenous ultra-short-acting benzodiazepine with the benefit of hemodynamic stability, including blood pressure and pulse rate. We report a case in which remimazolam was used in living donor liver transplantation with stable hemodynamics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 19-year-old woman underwent living donor liver transplantation due to end-stage liver disease, which is associated with a hyperdynamic state and hemodynamic instability. The patient\u2019s sister had a history of malignant hyperthermia, so we chose total intravenous anesthesia with remimazolam. Intraoperative bleeding of seven liters occurred, but she had mild intraoperative blood pressure changes, and continuous catecholamine administration was not necessary. The patient had no memories or discomfort during the surgery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We maintained stable hemodynamics using remimazolam for anesthetic management of a patient undergoing a liver transplantation, which is characterized by a hyperdynamic state and circulatory instability.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40981-022-00556-x","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T01:02:32Z","timestamp":1661130152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of remimazolam in living donor liver transplantation: a case report"],"prefix":"10.1186","volume":"8","author":[{"given":"Tsuguhiro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-0855","authenticated-orcid":false,"given":"Shuji","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"556_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40265-020-01299-8","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Remimazolam: first approval. Drugs. 2020;80:625\u201333. https:\/\/doi.org\/10.1007\/s40265-020-01299-8.","journal-title":"Drugs."},{"key":"556_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.anes.0000267503.85085.c0","volume":"107","author":"GJ Kilpatrick","year":"2007","unstructured":"Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107:60\u20136. https:\/\/doi.org\/10.1097\/01.anes.0000267503.85085.c0.","journal-title":"Anesthesiology."},{"key":"556_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00540-020-02788-6","volume":"34","author":"M Doi","year":"2020","unstructured":"Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb\/III trial. J Anesth. 2020;34:543\u201353. https:\/\/doi.org\/10.1007\/s00540-020-02788-6.","journal-title":"J Anesth"},{"key":"556_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.anclin.2017.04.006","volume":"35","author":"D Adelmann","year":"2017","unstructured":"Adelmann D, Kronish K, Ramsay MA. Anesthesia for liver transplantation. Anesthesiol Clin. 2017;35:491\u2013508. https:\/\/doi.org\/10.1016\/j.anclin.2017.04.006.","journal-title":"Anesthesiol Clin"},{"key":"556_CR5","doi-asserted-by":"publisher","first-page":"8845129","DOI":"10.1155\/2021\/8845129","volume":"2021","author":"T Watanabe","year":"2021","unstructured":"Watanabe T, Miyoshi H, Noda Y, Narasaki S, Morio A, Toyota Y, et al. Effects of remimazolam and propofol on Ca2+ regulation by ryanodine receptor 1 with malignant hyperthermia mutation. Biomed Res Int. 2021;2021:8845129. https:\/\/doi.org\/10.1155\/2021\/8845129.","journal-title":"Biomed Res Int"},{"key":"556_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40981-021-00482-4","volume":"7","author":"K Uchiyama","year":"2021","unstructured":"Uchiyama K, Sunaga H, Katori N, Uezono S. General anesthesia with remimazolam in a patient with clinically suspected malignant hyperthermia. JA Clin Rep. 2021;7:78. https:\/\/doi.org\/10.1186\/s40981-021-00482-4.","journal-title":"JA Clin Rep"},{"key":"556_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1213\/ANE.0b013e31823f0c28","volume":"115","author":"LJ Antonik","year":"2012","unstructured":"Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115:274\u201383. https:\/\/doi.org\/10.1213\/ANE.0b013e31823f0c28.","journal-title":"Anesth Analg"},{"key":"556_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","volume":"127","author":"T St\u00f6hr","year":"2021","unstructured":"St\u00f6hr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127:415\u201323. https:\/\/doi.org\/10.1016\/j.bja.2021.05.027.","journal-title":"Br J Anaesth"},{"key":"556_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/ALN.0000000000003102","volume":"132","author":"A Eisenried","year":"2020","unstructured":"Eisenried A, Sch\u00fcttler J, Lerch M, Ihmsen H, Jeleazcov C. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology. 2020;132:652\u201366. https:\/\/doi.org\/10.1097\/ALN.0000000000003102 PMID: 31972657.","journal-title":"Anesthesiology"}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-022-00556-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40981-022-00556-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-022-00556-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T01:02:35Z","timestamp":1661130155000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaclinicalreports.springeropen.com\/articles\/10.1186\/s40981-022-00556-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1186\/s40981-022-00556-x","relation":{},"ISSN":["2363-9024"],"issn-type":[{"value":"2363-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In our hospital, the publication of case reports is exempted from ethics committee approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from the patient and the parents of the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}